Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling

BACKGROUND: Darunavir 800 mg once (q24h) or 600 mg twice (q12h) daily combined with low-dose ritonavir is used to treat HIV-positive pregnant women. Decreased total darunavir exposure (17%–50%) has been reported during pregnancy, but limited data on unbound exposure are available. OBJECTIVES: To eva...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Antimicrob Chemother
Egile Nagusiak: Schalkwijk, Stein, ter Heine, Rob, Colbers, Angela, Capparelli, Edmund, Best, Brookie M, Cressey, Tim R, Greupink, Rick, Russel, Frans G M, Moltó, José, Mirochnick, Mark, Karlsson, Mats O, Burger, David M
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2019
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477987/
https://ncbi.nlm.nih.gov/pubmed/30715324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dky567
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak